ARCH leads $130M infusion into Be Bio's long pursuit of B cell therapies for rare disease, cancer
When Be Biopharma revealed itself a year and a half ago with $52 million, the Longwood-founded startup was confident about its vision of creating a new class of medicines out of B cells — but not quite sure yet where it would start. The company, which licensed its B cell engineering platform from Seattle Children’s Hospital, had only two employees.
Now, with 64 on staff — led by CEO Joanne Smith-Farrell and CSO Rick Morgan, both bluebird vets — Be Bio is finally ready to declare the initial areas of focus. And ARCH Venture Partners is hopping in to lead a $130 million round to lay the long path toward the clinic.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,900+ biopharma pros reading Endpoints daily — and it's free.